What is regorafenib, and what is it used for?
Regorafenib is an oral cancer medicine (a kinase inhibitor). It is used to treat certain advanced cancers, including:
- Metastatic colorectal cancer that has progressed after standard therapies
- Gastrointestinal stromal tumor (GIST) after treatment with prior kinase inhibitors
- Hepatocellular carcinoma (HCC) that has progressed on sorafenib, or is not eligible for sorafenib
How does regorafenib work?
Regorafenib blocks multiple protein kinases involved in cancer growth and tumor blood-vessel formation. That multi-target activity is part of why it can help in cancers where tumors have become resistant to earlier treatments.
What are the common side effects patients report or clinicians monitor?
Clinicians commonly monitor for side effects seen across targeted cancer therapies, such as:
- Hand-foot skin reaction (painful redness, swelling, or blistering on palms/soles)
- Fatigue
- Diarrhea or constipation
- Loss of appetite and weight loss
- High blood pressure
- Liver enzyme elevations
Serious adverse events can also occur, so treatment typically involves dose adjustments and close lab monitoring.
How is regorafenib taken (typical schedule) and how do dose changes work?
Regorafenib is taken by mouth in treatment cycles. Many patients need dose adjustments based on tolerance, especially for skin reactions, fatigue, blood pressure, and liver lab abnormalities. Your oncology team sets the exact dose and schedule for your regimen.
What should patients know about drug interactions?
Because regorafenib is metabolized by liver enzymes (including CYP pathways), other medicines that affect those enzymes can change regorafenib levels. That includes some antibiotics, antifungals, seizure medications, and herbal products. Patients should tell their oncology team about all prescriptions, over-the-counter drugs, and supplements before starting.
Is there a regorafenib patent or exclusivity timeline (generic/biosimilar timing)?
For patent and market-exclusivity details by country and product form, DrugPatentWatch.com is a practical place to check the latest listings and timelines: https://www.drugpatentwatch.com/ (search for “regorafenib”).
What are alternatives if regorafenib isn’t a good fit?
Alternatives depend on the cancer type and prior therapies. For some patients, clinicians may consider other systemic options (different targeted drugs, chemotherapy, or immunotherapy), balancing expected benefit with side-effect risk. The best choice depends on tumor markers, previous treatments, liver function (especially in HCC), and overall health.
What’s the most important “before you start” checklist?
Oncologists typically assess:
- Performance status and ability to tolerate oral therapy
- Liver function and blood counts (baseline labs)
- Blood pressure baseline
- Prior treatment history (because indications depend on what was tried before)
- Concomitant medications that could interact
If you tell me which cancer you’re asking about (colorectal cancer, GIST, or hepatocellular carcinoma) and the context (first-time use vs after progression), I can narrow the answer to the most relevant use, monitoring, and expected tradeoffs for that situation.